President Xi supports COVID-19 waiver
01-06-2021
AIPPI weighs in on COVID waiver
17-05-2021
AstraZeneca sues Dr Reddy's over breast cancer drug
14-02-2017
Dr Reddy’s secures thrombosis drug rights in $17.5m deal
27-11-2015
Pavel Kapysh / Shutterstock.com
India-based generics drug maker Dr. Reddy's Laboratories has entered into a voluntary licensing agreement with Eli Lilly to expand access to COVID-19 treatment in India.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Dr Reddy’s, COVID-19, Biden, IP waiver, Eli Lilly, baricitinib, licensing
